Day: September 13, 2022

Key HighlightsRecord revenue of $59.0 million (+647% YoY) Record Adjusted EBITDA of $26.2 million (+1,791% YoY)1 Record Adjusted EBITDA Margin of 44% (+144% YoY)2 Record cash flow from operations of $21.6 million (+1,124% YoY) Record average operating hashrate of 747 PH/s (+611% YoY) and 1,398 Bitcoin mined (+422% YoY) from 100% renewable energy powered operations since inception3 $110.0 million cash and cash equivalents as of June 30, 2022 and no corporate debt4 Post financial year end:Agreement reached with Bitmain to ship an additional 1.7 EH/s of miners, increasing total expected Company operating capacity from 4.3 EH/s to 6.0 EH/s 1.5 EH/s (50MW) at Mackenzie (BC, Canada) energized ahead of schedule 1.4 EH/s (50MW) at Prince George (BC, Canada) on track for September 2022 Company operating capacity guidance increased from 4.3...

Sales totaled $15.2 million Net loss of $4.8 million Adjusted EBITDA amounted to a loss of $2.1 million Cash position of $19.0 million and new, unused $15.0 million revolving credit facilityMONTREAL, Sept. 13, 2022 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (Nasdaq: DTEA) (“DAVIDsTEA” or the “Company”), a leading tea merchant in North America, announced today its second quarter results for the period ended July 30, 2022. “DAVIDsTEA continues to experience volatility in its channels. Our wholesale business in Canada expanded in the second quarter of 2022 with sales more than doubling year-over-year on the strength of a growing footprint at grocery stores, pharmacies and big-box locations to over 3,800 doors, including a wider assortment of wellness-focused and organic products. We are launching a new sachet format that will be available...

Diversified business, omnichannel marketing and acquisitions drove revenue growth in all segments Fourth quarter business-to-business (“B2B”) sales grew 55% while strong tasting room traffic drove 10% organic growth in direct-to-consumer (“DTC”) Made significant progress to improve internal controls; implemented stringent processes around inventory management and financial processes that resulted in $19.1 million in non-cash inventory adjustments Fourth quarter net loss was $14.7 million reflecting non-cash inventory adjustments; adjusted net income improved to $10.0 million and adjusted EBITDA1 was $7.6 million Fiscal 22 revenue grew 33% to $293.8 million; net loss for the year was $(0.7) million, adjusted net income expanded to $25.2 million and adjusted EBTIDA1 was $46.8 million, up 21% over the prior year Continue...

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – SAN DIEGO and TAICANG, China, Sept. 13, 2022 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global, clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced financial results for the six-month period ended June 30 and recent corporate highlights. “2022 has been a dynamic year for Connect Biopharma so far, with clinical progress in all three of our drug candidates, CBP-201, in atopic dermatitis (AD) (Global Phase 2b trial), CBP-307 (Phase 2), in ulcerative colitis (UC), and recently announced positive data for our...

DENVER, Sept. 13, 2022 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced financial results for its fiscal fourth quarter and full year ended June 30, 2022. “We ended the fiscal year with a census of approximately 6,650 participants and generated $698.6 million of revenue. Our results reflect the ongoing transformational journey at InnovAge and the core investments we are making in our business,” said Patrick Blair, President and Chief Executive Officer of InnovAge. “We have made measurable progress on our near-term operational improvements and strengthening our enterprise capabilities, and I am confident that we are on the right path to achieve our long-term aspirations for the Company.”Financial...

Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth quarter 2022Enrollment continuing in LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancerCash and investments of $110.7 million as of June 30, 2022, providing approximately two years of cash runwayAppointed James Noble and Jay Backstrom, M.D., M.P.H., as non-executive directors to the Company’s board of directorsUTRECHT, The Netherlands and PHILADELPHIA, Sept. 13, 2022 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T...

MITCHEL FIELD, N.Y., Sept. 13, 2022 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is reporting revenues for the first quarter ended July 31, 2022, of approximately $8.2 million compared to revenues of $13.0 million for the first quarter of fiscal 2022, ended July 31, 2021. Operating loss for the first quarter of fiscal 2023 was $3.1 million compared to an operating loss of $1.7 million for the same period of fiscal 2022. Net loss from operations was $3.1 million or ($0.33) per diluted share compared to a net loss of $1.6 million or ($0.17) per diluted share for the first quarter of fiscal year 2022. FEI Interim President and CEO, Thomas McClelland commented, “The first quarter of fiscal 2023, continued to be challenging financially, but aggressive steps to correct things are in progress....

Marketing spend decrease in Q4 2022 resulted in modest revenue decline in Q1 2023 Restructuring and lower marketing spend expected to reduce total spending by $4.4 million in Q2 and $4.9 million per quarter in Q3 and Q4 of fiscal year 2023 Continued corporate overhead controls drive sequential reduction in G&ANEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Aspen Group, Inc. (Nasdaq: ASPU) (“AGI”), an education technology holding company, today announced financial results for its first quarter fiscal year 2023 ended July 31, 2022. First Quarter Fiscal Year 2023 Summary Results  Three Months Ended July 31,$ in millions, except per share data   2022       2021  Revenue $ 18.9     $ 19.4  Gross Profit1 $ 8.2     $ 10.4  Gross Margin (%)1   43 %     54 %Net Income (Loss) $ (3.7 )   $ (0.9 )Earnings (Loss) per...